Accuray (NASDAQ:ARAY) & Adagio Medical (NASDAQ:ADGM) Head to Head Review

Accuray (NASDAQ:ARAY) and Adagio Medical (NASDAQ:ADGM) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Valuation and Earnings

This table compares Accuray and Adagio Medical”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Accuray	$401.95 million	0.07	-$49.19 million	($0.40)	-0.59
Adagio Medical	$600,000.00	18.55	-$25.08 million	($1.48)	-0.34

Adagio Medical has lower revenue, but higher earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Adagio Medical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Accuray and Adagio Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Accuray	-12.24%	-97.85%	-10.82%
Adagio Medical	N/A	-661.85%	-73.35%

Institutional and Insider Ownership

64.1% of Accuray shares are held by institutional investors. Comparatively, 48.1% of Adagio Medical shares are held by institutional investors. 2.4% of Accuray shares are held by company insiders. Comparatively, 7.8% of Adagio Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Risk & Volatility

Accuray has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500. Comparatively, Adagio Medical has a beta of -0.09, meaning that its stock price is 109% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for Accuray and Adagio Medical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Accuray	1	2	0	0	1.67
Adagio Medical	1	1	2	0	2.25

Accuray presently has a consensus price target of $2.00, indicating a potential upside of 751.06%. Adagio Medical has a consensus price target of $3.50, indicating a potential upside of 598.60%. Given Accuray’s higher possible upside, equities research analysts clearly believe Accuray is more favorable than Adagio Medical.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.

About Adagio Medical

Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. The company’s product portfolio includes iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories; vCLAS ventricular ULTC catheter; and Cryopulse atrial pulsed-field cryoablation catheter and accessories. The company is based in Laguna Hills, California.